Clinical Trials
The Agonist/Antagonist Duel for Enhanced Pharmaceuticals
This is the first posting from Scott Alexander. For more information about Scott, click the Author link on this page.
One of the persistent challenges of the Pharmaceutical industry has been maintaining the safety and efficacy of drug products in patients over time. In other words, when a patient starts taking the drug, the patient [...]
Professional Lab Rats
For those of you who know me, you know that I rarely take a pill if I don’t absolutely need to. It’s not that I necessarily think medicines don’t have their place as a solution for what ails me; rather, I am cautious about over-using drugs, regardless of whether it’s a simple painkiller or [...]
The Pipeline Floodeth
My latest issue of the Pharmaceutical Executive recently came in the mail, its cover heralding its report on the 2007 pipeline for drug companies. The story covers 61 offerings that are being developed at the big pharmaceutical companies to treat a variety of diseases. I examined it with great interest, taking particular note [...]
From Mighty Mice to Mighty Humans
On Tuesday, I wrote a post about studies that have been done by researchers that have, either accidentally or purposefully, modified mice to have extraordinary characteristics beyond those of their wild counterparts. In one study on metabolism, scientists modified the genes in their subjects to yield a mouse that displayed evidence of increased athletic [...]
FDA Balancing Act
The Food and Drug Administration (FDA) has come under a lot of scrutiny lately over safety concerns of approved drugs that were on the market but had to be recalled because of some serious adverse events reported by their customers. We can view mainly Merk’s Vioxx as the catalyst for this interest and examination [...]
Loading ...